ZYUS ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About ZYUS Life Sciences (CVE: ZYUS)
›
ZYUS Life Sciences (CVE: ZYUS) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.4000 CAD on 18 November 2026, down 42.9% over 52 weeks. Its 52-week range is 0.3000 CAD to 0.7500 CAD: the price is 46.7% below the high and 33.3% above the low.
Its market capitalisation is 32.03M CAD.
ZYUS Life Sciences reports return on equity of 102.9% and revenue down 32.5% year over year.
Its debt exceeds its cash by 23.64M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 November 2026.